Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 2023 Jan 17;20(1):e1004154.
doi: 10.1371/journal.pmed.1004154. eCollection 2023 Jan.
Peter Hanlon 1, Anoop S V Shah 2, Laurie J Hannigan 3 4 5, Emma McIntosh 1, Jim Lewsey 1, Sarah H Wild 6, Bruce Guthrie 6, Frances S Mair 1, David M Kent 7, Sofia Dias 8, Nicky J Welton 4, David A McAllister 1
Affiliations
- PMID: 36649256
- PMCID: PMC9844862
- DOI: 10.1371/journal.pmed.1004154
Meta-Analysis
Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis
Elaine W Butterly et al. PLoS Med. 2023.
Abstract
Background: Health-related quality of life metrics evaluate treatments in ways that matter to patients, so are often included in randomised clinical trials (hereafter trials). Multimorbidity, where individuals have 2 or more conditions, is negatively associated with quality of life. However, whether multimorbidity predicts change over time or modifies treatment effects for quality of life is unknown. Therefore, clinicians and guideline developers are uncertain about the applicability of trial findings to people with multimorbidity. We examined whether comorbidity count (higher counts indicating greater multimorbidity) (i) is associated with quality of life at baseline; (ii) predicts change in quality of life over time; and/or (iii) modifies treatment effects on quality of life.
Methods and findings: Included trials were registered on the United States trials registry for selected index medical conditions and drug classes, phase 2/3, 3 or 4, had ≥300 participants, a nonrestrictive upper age limit, and were available on 1 of 2 trial repositories on 21 November 2016 and 18 May 2018, respectively. Of 124 meeting these criteria, 56 trials (33,421 participants, 16 index conditions, and 23 drug classes) collected a generic quality of life outcome measure (35 EuroQol-5 dimension (EQ-5D), 31 36-item short form survey (SF-36) with 10 collecting both). Blinding and completeness of follow up were examined for each trial. Using trials where individual participant data (IPD) was available from 2 repositories, a comorbidity count was calculated from medical history and/or prescriptions data. Linear regressions were fitted for the association between comorbidity count and (i) quality of life at baseline; (ii) change in quality of life during trial follow up; and (iii) treatment effects on quality of life. These results were then combined in Bayesian linear models. Posterior samples were summarised via the mean, 2.5th and 97.5th percentiles as credible intervals (95% CI) and via the proportion with values less than 0 as the probability (PBayes) of a negative association. All results are in standardised units (obtained by dividing the EQ-5D/SF-36 estimates by published population standard deviations). Per additional comorbidity, adjusting for age and sex, across all index conditions and treatment comparisons, comorbidity count was associated with lower quality of life at baseline and with a decline in quality of life over time (EQ-5D -0.02 [95% CI -0.03 to -0.01], PBayes > 0.999). Associations were similar, but with wider 95% CIs crossing the null for SF-36-PCS and SF-36-MCS (-0.05 [-0.10 to 0.01], PBayes = 0.956 and -0.05 [-0.10 to 0.01], PBayes = 0.966, respectively). Importantly, there was no evidence of any interaction between comorbidity count and treatment efficacy for either EQ-5D or SF-36 (EQ-5D -0.0035 [95% CI -0.0153 to -0.0065], PBayes = 0.746; SF-36-MCS (-0.0111 [95% CI -0.0647 to 0.0416], PBayes = 0.70 and SF-36-PCS -0.0092 [95% CI -0.0758 to 0.0476], PBayes = 0.631.
Conclusions: Treatment effects on quality of life did not differ by multimorbidity (measured via a comorbidity count) at baseline-for the medical conditions studied, types and severity of comorbidities and level of quality of life at baseline, suggesting that evidence from clinical trials is likely to be applicable to settings with (at least modestly) higher levels of comorbidity.
Trial registration: A prespecified protocol was registered on PROSPERO (CRD42018048202).
Copyright: © 2023 Butterly et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests. NJW has received honoraria for training and masterclasses from: Association of British Pharmaceutical Industries, Campbell Ireland, Centre for Global Development, NICE International and NICE Scientific Advice, All Wales Therapeutics and Toxicology Centre, University of Leuven. NJW has delivered training for Takeda, ICON plc, and University of Galway for which payment was made to her institution. DM has received funding for this work from the Wellcome Trust.
Figures
Fig 1. PRISMA diagram for included trials in quality of life analyses.
Flow diagram of included trials with IPD and reporting QoL measures; EQ-5D or the 36-item short form survey (SF-36). IPD, individual participant data; QoL, quality of life.
Fig 2. EQ-5D, SF-36-PCS, and SF-36-MCS: change in quality of life and treatment interaction by condition.
The association of comorbidity and change in quality of life measures with treatment interaction (orange) and without (black). Standardised effect estimates with 50%, 80%, and 95% credibility intervals per trial index condition. EQ-5D, EuroQol-5 dimension; MCS, mental component score; PCS, physical component score; SF-36, the 36-item short form survey.
Fig 3. EQ-5D, SF-36-PCS and SF-36-MCS: change in quality of life and treatment interaction by treatment comparison.
The association of comorbidity and change in quality of life measures with treatment interaction (orange) and without (black). Standardised effect estimates with 50%, 80%, and 95% credibility intervals per trial intervention ATC drug treatment comparisons. ATC, anatomic therapeutic chemical; EQ-5D, EuroQol-5 dimension; MCS, mental component score; PCS; physical component score; SF-36, the 36-item short form survey.
Similar articles
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article. - Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trials.
Lees JS, Hanlon P, Butterly EW, Wild SH, Mair FS, Taylor RS, Guthrie B, Gillies K, Dias S, Welton NJ, McAllister DA. Lees JS, et al. BMJ Med. 2022 Sep 1;1(1):e000217. doi: 10.1136/bmjmed-2022-000217. eCollection 2022. BMJ Med. 2022. PMID: 36936559 Free PMC article. - Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5.
Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Kurosawa S, et al. Transplant Cell Ther. 2021 Nov;27(11):935.e1-935.e9. doi: 10.1016/j.jtct.2021.07.026. Epub 2021 Aug 8. Transplant Cell Ther. 2021. PMID: 34371214 - Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain.
Obradovic M, Lal A, Liedgens H. Obradovic M, et al. Health Qual Life Outcomes. 2013 Jul 1;11:110. doi: 10.1186/1477-7525-11-110. Health Qual Life Outcomes. 2013. PMID: 23815777 Free PMC article. Review. - Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
Taylor RS, Walker S, Ciani O, Warren F, Smart NA, Piepoli M, Davos CH. Taylor RS, et al. Health Technol Assess. 2019 May;23(25):1-98. doi: 10.3310/hta23250. Health Technol Assess. 2019. PMID: 31140973 Free PMC article. Review.
Cited by
- Description of subgroup reporting in clinical trials of chronic diseases: a meta-epidemiological study.
Wei L, Butterly E, Rodríguez Pérez J, Chowdhury A, Shemilt R, Hanlon P, McAllister D. Wei L, et al. BMJ Open. 2024 Jun 21;14(6):e081315. doi: 10.1136/bmjopen-2023-081315. BMJ Open. 2024. PMID: 38908852 Free PMC article. - COPD Assessment Test and risk of readmission in patients with bronchiectasis: a prospective cohort study.
Wang J, Chen X, He S, Li J, Ma T, Liu L, Zhang L, Bu X. Wang J, et al. ERJ Open Res. 2024 Mar 18;10(2):00867-2023. doi: 10.1183/23120541.00867-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38500792 Free PMC article. - A randomized controlled trial to evaluate the impact of pharmacist-led clinical interventions on the health-related quality of life among TB patients.
Khan FU, Khan FU, Aqeel MT, Hayat K, Chang J, Rehman AU, Fang Y. Khan FU, et al. Front Pharmacol. 2023 May 24;14:1171985. doi: 10.3389/fphar.2023.1171985. eCollection 2023. Front Pharmacol. 2023. PMID: 37292150 Free PMC article. - Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials.
Hanlon P, Butterly EW, Shah AS, Hannigan LJ, Lewsey J, Mair FS, Kent DM, Guthrie B, Wild SH, Welton NJ, Dias S, McAllister DA. Hanlon P, et al. PLoS Med. 2023 Jun 6;20(6):e1004176. doi: 10.1371/journal.pmed.1004176. eCollection 2023 Jun. PLoS Med. 2023. PMID: 37279199 Free PMC article. - A mobile app for chronic disease self-management for individuals with low health literacy: A multisite randomized controlled clinical trial.
Ownby RL, Waldrop D, Davenport R, Simonson M, Caballero J, Thomas-Purcell K, Purcell D, Ayala V, Gonzalez J, Patel N, Kondwani K. Ownby RL, et al. medRxiv [Preprint]. 2023 Apr 3:2023.04.01.23288020. doi: 10.1101/2023.04.01.23288020. medRxiv. 2023. PMID: 37066256 Free PMC article. Preprint.
References
- EQ-5D User Guides–EQ-5D. [cited 2021 Nov 19]. Available from: https://euroqol.org/publications/user-guides/.
- Hanlon P, Butterly E, Shah AS, Hannigan LJ, Wild SH, Guthrie B, et al.. Assessing trial representativeness using Serious Adverse Events: An observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data. BMC Med. 2022. doi: 10.1186/s12916-022-02594-9 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- MR/S021949/1/MRC_/Medical Research Council/United Kingdom
- MR/P015298/1/MRC_/Medical Research Council/United Kingdom
- 201492/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- MR/R025223/1/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources